Quarterly report · Q3
4483.TEDINET S100SUYD
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥22.3bn | 2023-04-01 → 2023-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥8.5bn | 2023-10-01 → 2023-12-31d | Cons. | Revenue IFRS |
| Revenue | ¥27.8bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥19.5bn | 2022-04-01 → 2022-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥7.5bn | 2022-10-01 → 2022-12-31d | Cons. | Revenue IFRS |
| Operating income | ¥5.7bn | 2023-04-01 → 2023-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥2.1bn | 2023-10-01 → 2023-12-31d | Cons. | Operating profit loss IFRS |
| Operating income | ¥4.0bn | 2022-04-01 → 2022-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.8bn | 2022-10-01 → 2022-12-31d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥5.6bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥2.0bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥5.9bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥4.0bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.8bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥4.0bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥1.3bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥4.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.7bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥1.2bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥4.0bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥1.3bn | 2023-10-01 → 2023-12-31d | Cons. | Profit loss IFRS |
| Net income | ¥2.7bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥1.2bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss IFRS |
| Total assets | ¥103.6bn | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥98.6bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥95.1bn | at 2022-12-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥33.6bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥34.0bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥70.0bn | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥64.5bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥62.9bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥31.2bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥70.0bn | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥64.5bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥62.9bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥17.0bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥22.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥21.8bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥13.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥1.2bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥4.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥2.5bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥9.4bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥22.8bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥21.8bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥2.4bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥28.3bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥27.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥62.31 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥20.14 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥71.17 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥44.98 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥19.28 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥60.44 | 2023-04-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥19.91 | 2023-10-01 → 2023-12-31d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥67.69 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥42.66 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥18.45 | 2022-10-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 67.5% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 65.5% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 66.1% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥102m |
| Reconciling Itemsreconciling | revenue | 2023-10-01 → 2023-12-31 | −¥12m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥102m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-10-01 → 2023-12-31 | −¥12m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥515m |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2023-12-31 | −¥176m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2023-10-01 → 2023-12-31 | ¥301m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥1.5bn |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2023-10-01 → 2023-12-31 | ¥301m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥50m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥175m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2023-10-01 → 2023-12-31 | ¥41m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥16.6bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue | 2023-10-01 → 2023-12-31 | ¥6.8bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥16.6bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue external | 2023-10-01 → 2023-12-31 | ¥6.8bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥51m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2023-10-01 → 2023-12-31 | ¥12m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥5.0bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | segment profit | 2023-10-01 → 2023-12-31 | ¥2.5bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥4.2bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue | 2023-10-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥4.2bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue external | 2023-10-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | segment profit | 2023-10-01 → 2023-12-31 | ¥556m |
| —segment total | revenue | 2023-04-01 → 2023-12-31 | ¥22.4bn |
| —segment total | revenue | 2023-10-01 → 2023-12-31 | ¥8.5bn |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥22.3bn |
| —segment total | revenue external | 2023-10-01 → 2023-12-31 | ¥8.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥102m |
| —segment total | revenue intersegment | 2023-10-01 → 2023-12-31 | ¥12m |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | ¥6.7bn |
| —segment total | segment profit | 2023-10-01 → 2023-12-31 | ¥3.1bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥189m |
| Reconciling Itemsreconciling | revenue | 2022-10-01 → 2022-12-31 | −¥62m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥189m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-10-01 → 2022-12-31 | −¥62m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥417m |
| Reconciling Itemsreconciling | segment profit | 2022-10-01 → 2022-12-31 | −¥227m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥2.8bn |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥944m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥2.7bn |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥901m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥127m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-10-01 → 2022-12-31 | ¥43m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥310m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-10-01 → 2022-12-31 | ¥118m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥13.1bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥13.1bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥62m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-10-01 → 2022-12-31 | ¥19m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-10-01 → 2022-12-31 | ¥2.0bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥3.8bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥3.8bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | segment profit | 2022-10-01 → 2022-12-31 | ¥492m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥19.7bn |
| —segment total | revenue | 2022-10-01 → 2022-12-31 | ¥7.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥19.5bn |
| —segment total | revenue external | 2022-10-01 → 2022-12-31 | ¥7.5bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥189m |
| —segment total | revenue intersegment | 2022-10-01 → 2022-12-31 | ¥62m |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥5.7bn |
| —segment total | segment profit | 2022-10-01 → 2022-12-31 | ¥2.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 846
| Item | Context | Value | Unit |
|---|---|---|---|
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所(プライム市場) | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Text · Plus | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Voting rights (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsOtherMember | Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式であります。なお、単元株式数は100株であります。 | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)株式会社ＪＭＤＣ | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都港区芝大門二丁目５番５号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Description of fact that consolidated financial statements have been prepared in accordance with IFRS financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of financial position IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed year to quarter end consolidated statement of profit or loss IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarter period consolidated statement of profit or loss IFRS (text) | CurrentQuarterDuration | Text · Plus | |
| Condensed year to quarter end consolidated statement of comprehensive income IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarter period consolidated statement of comprehensive income IFRS (text) | CurrentQuarterDuration | Text · Plus | |
| Condensed quarterly consolidated statement of changes in equity IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of cash flows IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes reporting entity condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes basis of preparation condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant accounting policies condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant accounting estimates and judgements condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes business combinations condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes goodwill and intangible assets condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes share capital and other equity items condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes dividends condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes earnings per share condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes fair value of financial instruments condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes related parties condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes subsequent events condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |